| [1] |
刘景双, 刘向群. 肺炎克雷伯杆菌对碳青霉烯类的耐药机制. 临床肺科杂志, 2017, 22(6):1122-1125. doi:10.3969/j.issn.1009-6663.2017.06.044.
doi: 10.3969/j.issn.1009-6663.2017.06.044
|
| [2] |
胡付品, 郭燕, 朱德妹, 等. 2021年CHINET中国细菌耐药监测. 中国感染与化疗杂志, 2022, 22(5): 521-530. doi:10.16718/j.1009-7708.2022.05.001.
doi: 10.16718/j.1009-7708.2022.05.001
|
| [3] |
Chen YC, Chiu SK, Lin TY, et al. Metastatic abscess formation in a preexisting chest wall tumor: a rare initial presentation of Klebsiella pneumoniae liver abscess. Infection, 2013, 41(5):1051-1052. doi:10.1007/s15010-013-0446-7.
doi: 10.1007/s15010-013-0446-7
pmid: 23526295
|
| [4] |
袁洪志, 唐莉鸿, 廉亮亮. 外伤后迟发性胸壁脓肿13例的外科治疗. 中国微创外科杂志, 2016, 16(2): 187-188. doi:10.3969/j.issn.1009-6604.2016.02.025.
doi: 10.3969/j.issn.1009-6604.2016.02.025
|
| [5] |
Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med, 2014, 370(13):1198-1208. doi:10.1056/NEJMoa1306801.
doi: 10.1056/NEJMoa1306801
URL
|
| [6] |
胡小品, 袁国航, 吴瑶瑶, 等. 中国西南地区3所综合性医院耐碳青霉烯类肺炎克雷伯菌流行病学特征及耐药性. 中国感染控制杂志, 2022, 21(2): 121-127. doi:10.12138/j.issn.1671-9638.20221872.
doi: 10.12138/j.issn.1671-9638.20221872
|
| [7] |
Martin RM, Bachman MA. Colonization, Infection, and the Accessory Genome of Klebsiella pneumoniae. Front Cell Infect Microbiol, 2018, 22,8:4. doi:10.3389/fcimb.2018.00004.
doi: 10.3389/fcimb.2018.00004
|
| [8] |
马红映, 汪丽, 虞亦鸣, 等. 院内获得耐碳青霉烯类抗菌药物肺炎克雷伯菌感染的危险因素分析. 中华医院感染学杂志, 2017, 27(7): 1456-1458. doi:10.11816/cn.ni.2017-162574.
doi: 10.11816/cn.ni.2017-162574
|
| [9] |
Kitsios GD. Translating Lung Microbiome Profiles into the Next-Generation Diagnostic Gold Standard for Pneumonia: a Clinical Investigator’s Perspective. mSystems, 2018, 3(2):e00153-17. doi:10.1128/mSystems.00153-17.
doi: 10.1128/mSystems.00153-17
|
| [10] |
Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, et al. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother, 2008, 52(3):1028-1033. doi:10.1128/AAC.01020-07.
doi: 10.1128/AAC.01020-07
URL
|
| [11] |
Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect, 2022, 28(4):521-547. doi:10.1016/j.cmi.2021.11.025.
doi: 10.1016/j.cmi.2021.11.025
URL
|
| [12] |
赵润芝, 刘佳欣, 叶寰. 耐碳青霉烯肺炎克雷伯菌治疗手段研究进展. 中国初级卫生保健, 2020, 34(9): 86-88. doi:10.3969/j.issn.1001-568X.2020.09.0025.
doi: 10.3969/j.issn.1001-568X.2020.09.0025
|
| [13] |
陈涛, 徐晔, 董郭枫, 等. 头孢他啶/阿维巴坦单独和联合磷霉素碳青霉烯类耐药革兰阴性菌体外抗菌活性研究. 检验医学, 2020, 35(10): 988-893. doi:10.3969/j.issn.1673-8640.2020.10.006.
doi: 10.3969/j.issn.1673-8640.2020.10.006
|
| [14] |
Shirley M. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections. Drugs, 2018, 78(6):675-692. doi:10.1007/s40265-018-0902-x.
doi: 10.1007/s40265-018-0902-x
pmid: 29671219
|
京公安网备11010202008787号
ip访问总数: ip当日访问总数: 当前在线人数:
本作品遵循Creative Commons Attribution 3.0 License授权许可
